| Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP |
16 |
| Gastrointestinal hormones and regulation of gastric emptying |
12 |
| Carcinoid-syndrome: recent advances, current status and controversies |
12 |
| Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes |
11 |
| Potential mechanisms underlying the effect of bariatric surgery on eating behaviour |
10 |
| Bone health in type 1 diabetes |
9 |
| Updates on the biology of serotonin and tryptophan hydroxylase |
9 |
| Dyslipidemia in nonalcoholic fatty liver disease |
8 |
| Long noncoding RNAs in thyroid cancer |
8 |
| Endocrine manifestations of Down syndrome |
8 |
| The current state of long-acting growth hormone preparations for growth hormone therapy |
8 |
| Weight stigma and its impact on paediatric care |
7 |
| Update in adrenal venous sampling for primary aldosteronism |
7 |
| Endocrine disrupters and pubertal timing |
7 |
| Central control of gastrointestinal motility |
7 |
| Impact of circadian rhythms on female reproduction and infertility treatment success |
6 |
| Evaluation of bone health in patients with adrenal tumors |
6 |
| Neutrophils and type 1 diabetes: current knowledge and suggested future directions |
6 |
| Pathophysiological relevance of deiodinase polymorphism |
6 |
| Evolving management considerations in active surveillance for micropapillary thyroid carcinoma |
6 |
| Updates on the neurobiology of food reward and their relation to the obesogenic environment |
5 |
| The gut microbiota in type 1 diabetes: friend or foe? |
5 |
| The catalytic role of iodine excess in loss of homeostasis in autoimmune thyroiditis |
5 |
| Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis |
5 |
| Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy |
4 |
| Technological advances shaping diabetes care |
4 |
| Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management |
4 |
| Androgen abuse epidemiology |
4 |
| Thyroid nodules in children and adolescents |
4 |
| The impact of age on thyroid cancer staging |
4 |
| Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D |
4 |
| Low cholesterol, impulsivity and violence revisited |
4 |
| Discordance between lipoprotein particle number and cholesterol content: an update |
4 |
| MicroRNAs: markers of -cell stress and autoimmunity |
3 |
| The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery |
3 |
| Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction |
3 |
| How does 'metabolic surgery' work its magic? New evidence for gut microbiota |
3 |
| Diabetes medications and cardiovascular disease: at long last progress |
3 |
| Immunotherapies for thyroid eye disease |
3 |
| Update on diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
3 |
| Androgens and depression: a review and update |
3 |
| Opioid induced adrenal insufficiency: what is new? |
3 |
| Risk factors for valvular calcification |
3 |
| Use of bone turnover markers in the management of osteoporosis |
3 |
| The role of circadian rhythm in male reproduction |
3 |
| The ongoing D-lemma of vitamin D supplementation for nonskeletal health and bone health |
3 |
| Updates in vitamin D therapy in cystic fibrosis |
2 |
| Physical activity in adolescents and children and relationship to metabolic health |
2 |
| Controversy over the atherogenicity of lipoprotein-X |
2 |
| Pitfalls in the interpretation of the cosyntropin stimulation test for the diagnosis of adrenal insufficiency |
2 |
